Cargando…

IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors

BACKGROUND: High serum interleukin (IL-6) levels may cause resistance to immunotherapy by modulation of myeloid cells in the tumor microenvironment. IL-6 signaling blockade is tested in cancer, but as this inflammatory cytokine has pleiotropic effects, this treatment is not always effective. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Beyranvand Nejad, Elham, Labrie, Camilla, van Elsas, Marit J, Kleinovink, Jan Willem, Mittrücker, Hans-Willi, Franken, Kees L M C, Heink, Sylvia, Korn, Thomas, Arens, Ramon, van Hall, Thorbald, van der Burg, Sjoerd H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061866/
https://www.ncbi.nlm.nih.gov/pubmed/33879600
http://dx.doi.org/10.1136/jitc-2021-002460
_version_ 1783681648936615936
author Beyranvand Nejad, Elham
Labrie, Camilla
van Elsas, Marit J
Kleinovink, Jan Willem
Mittrücker, Hans-Willi
Franken, Kees L M C
Heink, Sylvia
Korn, Thomas
Arens, Ramon
van Hall, Thorbald
van der Burg, Sjoerd H
author_facet Beyranvand Nejad, Elham
Labrie, Camilla
van Elsas, Marit J
Kleinovink, Jan Willem
Mittrücker, Hans-Willi
Franken, Kees L M C
Heink, Sylvia
Korn, Thomas
Arens, Ramon
van Hall, Thorbald
van der Burg, Sjoerd H
author_sort Beyranvand Nejad, Elham
collection PubMed
description BACKGROUND: High serum interleukin (IL-6) levels may cause resistance to immunotherapy by modulation of myeloid cells in the tumor microenvironment. IL-6 signaling blockade is tested in cancer, but as this inflammatory cytokine has pleiotropic effects, this treatment is not always effective. METHODS: IL-6 and IL-6R blockade was applied in an IL-6-mediated immunotherapy-resistant TC-1 tumor model (TC-1.IL-6) and immunotherapy-sensitive TC-1.control. Effects on therapeutic vaccination-induced tumor regression, recurrence and survival as well on T cells and myeloid cells in the tumor microenvironment were studied. The effects of IL-6 signaling in macrophages under therapy conditions were studied in Il6ra(fl/fl)×LysM(cre+) mice. RESULTS: Our therapeutic vaccination protocol elicits a strong tumor-specific CD8(+) T-cell response, leading to enhanced intratumoral T-cell infiltration and recruitment of tumoricidal macrophages. Blockade of IL-6 signaling exacerbated tumor outgrowth, reflected by fewer complete regressions and more recurrences after therapeutic vaccination, especially in TC-1.IL-6 tumor-bearing mice. Early IL-6 signaling blockade partly inhibited the development of the vaccine-induced CD8(+) T-cell response. However, the main mechanism was the malfunction of macrophages during therapy-induced tumor regression. Therapy efficacy was impaired in Il6ra(fl/fl)×LysM(cre+) but not cre-negative control mice, while no differences in the vaccine-induced CD8(+) T-cell response were found between these mice. IL-6 signaling blockade resulted in decreased expression of suppressor of cytokine signaling 3, essential for effective M1-type function in macrophages, and increased expression of the phagocytic checkpoint molecule signal-regulatory protein alpha by macrophages. CONCLUSION: IL-6 signaling is critical for macrophage function under circumstances of immunotherapy-induced tumor tissue destruction, in line with the acute inflammatory functions of IL-6 signaling described in infections.
format Online
Article
Text
id pubmed-8061866
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-80618662021-05-11 IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors Beyranvand Nejad, Elham Labrie, Camilla van Elsas, Marit J Kleinovink, Jan Willem Mittrücker, Hans-Willi Franken, Kees L M C Heink, Sylvia Korn, Thomas Arens, Ramon van Hall, Thorbald van der Burg, Sjoerd H J Immunother Cancer Basic Tumor Immunology BACKGROUND: High serum interleukin (IL-6) levels may cause resistance to immunotherapy by modulation of myeloid cells in the tumor microenvironment. IL-6 signaling blockade is tested in cancer, but as this inflammatory cytokine has pleiotropic effects, this treatment is not always effective. METHODS: IL-6 and IL-6R blockade was applied in an IL-6-mediated immunotherapy-resistant TC-1 tumor model (TC-1.IL-6) and immunotherapy-sensitive TC-1.control. Effects on therapeutic vaccination-induced tumor regression, recurrence and survival as well on T cells and myeloid cells in the tumor microenvironment were studied. The effects of IL-6 signaling in macrophages under therapy conditions were studied in Il6ra(fl/fl)×LysM(cre+) mice. RESULTS: Our therapeutic vaccination protocol elicits a strong tumor-specific CD8(+) T-cell response, leading to enhanced intratumoral T-cell infiltration and recruitment of tumoricidal macrophages. Blockade of IL-6 signaling exacerbated tumor outgrowth, reflected by fewer complete regressions and more recurrences after therapeutic vaccination, especially in TC-1.IL-6 tumor-bearing mice. Early IL-6 signaling blockade partly inhibited the development of the vaccine-induced CD8(+) T-cell response. However, the main mechanism was the malfunction of macrophages during therapy-induced tumor regression. Therapy efficacy was impaired in Il6ra(fl/fl)×LysM(cre+) but not cre-negative control mice, while no differences in the vaccine-induced CD8(+) T-cell response were found between these mice. IL-6 signaling blockade resulted in decreased expression of suppressor of cytokine signaling 3, essential for effective M1-type function in macrophages, and increased expression of the phagocytic checkpoint molecule signal-regulatory protein alpha by macrophages. CONCLUSION: IL-6 signaling is critical for macrophage function under circumstances of immunotherapy-induced tumor tissue destruction, in line with the acute inflammatory functions of IL-6 signaling described in infections. BMJ Publishing Group 2021-04-20 /pmc/articles/PMC8061866/ /pubmed/33879600 http://dx.doi.org/10.1136/jitc-2021-002460 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Basic Tumor Immunology
Beyranvand Nejad, Elham
Labrie, Camilla
van Elsas, Marit J
Kleinovink, Jan Willem
Mittrücker, Hans-Willi
Franken, Kees L M C
Heink, Sylvia
Korn, Thomas
Arens, Ramon
van Hall, Thorbald
van der Burg, Sjoerd H
IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors
title IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors
title_full IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors
title_fullStr IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors
title_full_unstemmed IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors
title_short IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors
title_sort il-6 signaling in macrophages is required for immunotherapy-driven regression of tumors
topic Basic Tumor Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061866/
https://www.ncbi.nlm.nih.gov/pubmed/33879600
http://dx.doi.org/10.1136/jitc-2021-002460
work_keys_str_mv AT beyranvandnejadelham il6signalinginmacrophagesisrequiredforimmunotherapydrivenregressionoftumors
AT labriecamilla il6signalinginmacrophagesisrequiredforimmunotherapydrivenregressionoftumors
AT vanelsasmaritj il6signalinginmacrophagesisrequiredforimmunotherapydrivenregressionoftumors
AT kleinovinkjanwillem il6signalinginmacrophagesisrequiredforimmunotherapydrivenregressionoftumors
AT mittruckerhanswilli il6signalinginmacrophagesisrequiredforimmunotherapydrivenregressionoftumors
AT frankenkeeslmc il6signalinginmacrophagesisrequiredforimmunotherapydrivenregressionoftumors
AT heinksylvia il6signalinginmacrophagesisrequiredforimmunotherapydrivenregressionoftumors
AT kornthomas il6signalinginmacrophagesisrequiredforimmunotherapydrivenregressionoftumors
AT arensramon il6signalinginmacrophagesisrequiredforimmunotherapydrivenregressionoftumors
AT vanhallthorbald il6signalinginmacrophagesisrequiredforimmunotherapydrivenregressionoftumors
AT vanderburgsjoerdh il6signalinginmacrophagesisrequiredforimmunotherapydrivenregressionoftumors